DB:CXF

Stock Analysis Report

Executive Summary

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases.


Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has Chimerix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CXF's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.6%

CXF

11.7%

DE Biotechs

9.9%

DE Market


1 Year Return

-31.7%

CXF

-8.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: CXF underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: CXF underperformed the German Market which returned -17.7% over the past year.


Shareholder returns

CXFIndustryMarket
7 Day-1.6%11.7%9.9%
30 Day-19.1%-5.9%-16.6%
90 Day-29.8%-22.6%-24.8%
1 Year-31.7%-31.7%-7.9%-8.1%-15.0%-17.5%
3 Year-78.7%-78.7%16.6%15.4%-17.4%-24.5%
5 Year-96.3%-96.3%-6.1%-8.5%-16.6%-28.1%

Price Volatility Vs. Market

How volatile is Chimerix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Chimerix undervalued compared to its fair value and its price relative to the market?

0.8x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CXF's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CXF's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CXF is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CXF is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CXF's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CXF is good value based on its PB Ratio (0.8x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Chimerix forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

17.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CXF is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CXF is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CXF is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CXF's revenue (15.6% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: CXF's revenue (15.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CXF's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Chimerix performed over the past 5 years?

0.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CXF is currently unprofitable.

Growing Profit Margin: CXF is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CXF is unprofitable, but has reduced losses over the past 5 years at a rate of 0.8% per year.

Accelerating Growth: Unable to compare CXF's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CXF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: CXF has a negative Return on Equity (-102.39%), as it is currently unprofitable.


Next Steps

Financial Health

How is Chimerix's financial position?


Financial Position Analysis

Short Term Liabilities: CXF's short term assets ($118.1M) exceed its short term liabilities ($9.2M).

Long Term Liabilities: CXF's short term assets ($118.1M) exceed its long term liabilities ($196.0K).


Debt to Equity History and Analysis

Debt Level: CXF is debt free.

Reducing Debt: CXF has no debt compared to 5 years ago when its debt to equity ratio was 1.6%.


Balance Sheet

Inventory Level: CXF has a low level of unsold assets or inventory.

Debt Coverage by Assets: CXF's debt is not covered by short term assets (assets are -1.0636871815901E+18x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CXF has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CXF has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -3.7% each year.


Next Steps

Dividend

What is Chimerix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CXF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CXF's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CXF's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CXF's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CXF's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Mike Sherman (53yo)

0.83

Tenure

Mr. Michael A. Sherman, also known as Mike, has been Chief Executive Officer of Chimerix, Inc. since April 8, 2019 and serves as President and Director since April 2019. Mr. Sherman served as the Chief Exe ...


Leadership Team

NamePositionTenureCompensationOwnership
William Nichols
Chief Medical Officer5.42yrsUS$1.00m0.23% $189.9k
Michael Sherman
CEO, President & Director0.83yrno data0.17% $141.1k
Michael Andriole
Chief Business Officer & CFO0.83yrno data0.24% $196.2k
David Jakeman
Executive Director of Finance & Accounting and Principal Accounting Officer0.67yrno data0.0048% $3.9k
Roy Ware
Chief Manufacturing & Technology Officer3.17yrsno datano data
Randall Lanier
Chief Science Officer3.17yrsno datano data
Michelle LaSpaluto
Vice President of Strategic Planning & Investor Relations4.17yrsno datano data
Michael Alrutz
Senior VP5.42yrsno data0.25% $205.3k

3.2yrs

Average Tenure

49yo

Average Age

Experienced Management: CXF's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Sherman
CEO, President & Director0.83yrno data0.17% $141.1k
Fred Middleton
Independent Director2yrsUS$272.50k0.32% $258.8k
Seth Rudnick
Member of Scientific Advisory Boardno datano datano data
Martha Demski
Chairman of the Board1.67yrsUS$134.53k0.060% $48.5k
Douglas Richman
Member of Scientific Advisory Boardno datano datano data
Michael Boeckh
Member of Clinical Advisory Boardno datano datano data
Earl Kern
Member of Scientific Advisory Boardno datano datano data
Raymund Razonable
Member of Clinical Advisory Boardno datano datano data
Robert Meyer
Independent Director2yrsUS$265.93k0.016% $13.1k
Edward Greissing
Independent Director2yrsUS$267.25kno data

2.0yrs

Average Tenure

67yo

Average Age

Experienced Board: CXF's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CXF insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.2%.


Top Shareholders

Company Information

Chimerix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Chimerix, Inc.
  • Ticker: CXF
  • Exchange: DB
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$88.907m
  • Listing Market Cap: US$80.905m
  • Shares outstanding: 61.74m
  • Website: https://www.chimerix.com

Number of Employees


Location

  • Chimerix, Inc.
  • 2505 Meridian Parkway
  • Suite 100
  • Durham
  • North Carolina
  • 27713
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CMRXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDApr 2013
CXFDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2013
CXFBRSE (Berne Stock Exchange)YesCommon StockCHCHFApr 2013

Biography

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of several key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an oral antiviral for the treatment of smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize DSTAT; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 22:56
End of Day Share Price2020/03/31 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.